NASDAQ · Biotechnology · USD

Vyome Holdings, Inc. (HIND) Stock Analysis

Vyome Holdings, Inc. (HIND) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HIND

$1.84

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HIND with… →

HIND Key Statistics

As of Oct 21, 2026

Trading

Open: $1.86
Previous Close: $1.84
Day's Range: 1.84–1.87
52-Week Range: 1.75–6.56
Volume: 2.23K

Valuation

Market Cap: $12.91M
P/S ratio: 99.55

Financials (FY)

Revenue (FY): $319.71K+24.43%
Net Income (FY): −$10.26M
Shares Outstanding: 7.02M
1-Year Return: −66.18%

Dividend and dates

Avg Volume: 12.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HIND closed at $1.84, −66.18% over 1 year.

Vyome Holdings, Inc. (HIND) has a market capitalization of $12.91M.

In fiscal 2025, HIND reported revenue of $319.71K.

HIND Stock Return by Calendar Year

Vyome Holdings, Inc. (HIND) return since Jan 2025: what $10,000 became

1 year: $10,000 $3,382; −66.18%
Since Jan 2025: $10,000 $41; −99.59%

If you had invested $10,000 in Vyome Holdings, Inc. (HIND) at the close on January 10, 2025, the earliest close on record here, it would have been worth $41 at the close on October 21, 2026: −99.59% in total, −95.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−46.51%
2025	−99.24%

As of October 21, 2026.

HIND Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$319.71K	−$10.26M	−3,209.7%
2024	$256.94K	−$1.45M	−563.3%
2023	$415.94K	−$719.92K	−173.1%
2022	$382.87K	−$1.26M	−327.9%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$319.71K	$218.77K	−$2.75M	−$10.26M	−3,209.7%
2024	$256.94K	$194.97K	−$1.01M	−$1.45M	−563.3%
2023	$415.94K	$282.53K	−$767.72K	−$719.92K	−173.1%
2022	$382.87K	$146.12K	−$1.10M	−$1.26M	−327.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HIND Valuation vs Biotechnology Median

Median of 608 stocks

Metric	HIND	Biotechnology median	vs median
P/S ratio	99.55	13.30	7.5x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Vyome Holdings, Inc. (HIND) carries a market capitalisation of $12.91M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 9.

HIND last closed at $1.84 on October 21, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $1.75 to $6.56. The latest close sits 5.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $319.71K. Against the prior fiscal year total of $256.94K, that is a change of +24.43%. The same year closed with a net loss of $10.26M.

Across the 4 fiscal years on file, revenue moves from $382.87K in 2022 to $319.71K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

Measured against sales, the shares trade at 99.55 times revenue. On price-to-sales that is 7.5 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −66.18%. The stored price history starts on January 10, 2025, and the total return since then is −99.59%. Daily returns over the trailing 1 year annualize to a volatility of 75.94%.

Growth & Income

No dividend is on file for HIND.

The record holds one complete calendar year, 2025, which returned −99.24%. So far in 2026 the total return is −46.51%.

Peer Comparison

Vyome Holdings, Inc. (HIND) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Vyome Holdings, Inc.	HIND	$12.91M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Vyome Holdings, Inc.

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Visit website →